(Q32050561)

5 July 2017

Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial (English)

1 reference

5 July 2017

0 references

0 references

1 reference

O Bruyere

6

0 references

author name string

J Y Reginster

1

1 reference

5 July 2017

R Deroisy

2

1 reference

5 July 2017

L C Rovati

3

1 reference

5 July 2017

R L Lee

4

1 reference

5 July 2017

E Lejeune

5

1 reference

5 July 2017

G Giacovelli

7

1 reference

5 July 2017

Y Henrotin

8

1 reference

5 July 2017

J E Dacre

9

1 reference

5 July 2017

C Gossett

10

1 reference

5 July 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

5 July 2017

1 reference

5 July 2017

357

1 reference

5 July 2017

251-256

1 reference

5 July 2017

9252

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903610-2

5 July 2017

1 reference

7 January 2021

Recommendations for the registration of drugs used in the treatment of osteoarthritis. Group for the respect of ethics and excellence in science (GREES): osteoarthritis section

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903610-2

7 January 2021

Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903610-2

7 January 2021

Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903610-2

7 January 2021

The biology of osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903610-2

7 January 2021

Glucosamine sulfate in osteoarthritis of the knee.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903610-2

7 January 2021

Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903610-2

7 January 2021

Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903610-2

7 January 2021

Glucosamine and chondroitin for treating symptoms of osteoarthritis: evidence is widely touted but incomplete

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903610-2

7 January 2021

Hype about glucosamine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903610-2

7 January 2021

The automatic assessment of knee radiographs in osteoarthritis using digital image analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903610-2

7 January 2021

Quantitative evaluation of joint space width in femorotibial osteoarthritis: comparison of three radiographic views

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903610-2

7 January 2021

Is conventional radiography suitable for evaluation of a disease-modifying drug in patients with knee osteoarthritis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903610-2

7 January 2021

The Bristol 'OA500' study: progression of osteoarthritis (OA) over 3 years and the relationship between clinical and radiographic changes at the knee joint

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903610-2

7 January 2021

Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903610-2

7 January 2021

Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903610-2

7 January 2021

10.1016/S0140-6736(00)03610-2

Identifiers

DOI

1 reference

5 July 2017

1 reference